Oscar Hevia1. 1. Private Practice, Miami, Florida, USA. liponet@aol.com
Abstract
BACKGROUND: The correction of infraorbital volume loss with dermal fillers results in a natural, youthful, rested appearance. Defects in this facial region should be treated for optimal patient satisfaction. OBJECTIVE: This retrospective review describes large-scale use of injection of calcium hydroxylapatite (CaHA) and a technique for injection into the infraorbital region. METHODS AND MATERIALS: Using a 30-gauge, 0.5 needle, CaHA was injected into the infraorbital region of 301 patients. Neat CaHA was initially twice diluted with lidocaine 2% solution in 85 patients. Subsequently, 216 patients were treated with single-dilution CaHA and 0.15 mL of 2% lidocaine. RESULTS: Injection of CaHa through a 30-gauge, 0.5 needle resulted in minimal bruising, discomfort, or pain. Infraorbital volume restoration was achieved efficiently and effectively, with natural results. Patients were satisfied with the longevity of correction. Adverse events were few and confined to ecchymosis (10%), edema (2%), and erythema (1%). Three of six patients reported edema lasting beyond 7 days. No overcorrection was observed. CONCLUSION: Using a 30-gauge, 0.5 needle, diluted CaHA can be safely injected into the infraorbital region with minimal adverse events and high patient satisfaction.
BACKGROUND: The correction of infraorbital volume loss with dermal fillers results in a natural, youthful, rested appearance. Defects in this facial region should be treated for optimal patient satisfaction. OBJECTIVE: This retrospective review describes large-scale use of injection of calcium hydroxylapatite (CaHA) and a technique for injection into the infraorbital region. METHODS AND MATERIALS: Using a 30-gauge, 0.5 needle, CaHA was injected into the infraorbital region of 301 patients. Neat CaHA was initially twice diluted with lidocaine 2% solution in 85 patients. Subsequently, 216 patients were treated with single-dilution CaHA and 0.15 mL of 2% lidocaine. RESULTS: Injection of CaHa through a 30-gauge, 0.5 needle resulted in minimal bruising, discomfort, or pain. Infraorbital volume restoration was achieved efficiently and effectively, with natural results. Patients were satisfied with the longevity of correction. Adverse events were few and confined to ecchymosis (10%), edema (2%), and erythema (1%). Three of six patients reported edema lasting beyond 7 days. No overcorrection was observed. CONCLUSION: Using a 30-gauge, 0.5 needle, diluted CaHA can be safely injected into the infraorbital region with minimal adverse events and high patient satisfaction.